Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Objective
Immune checkpoint inhibitors (ICIs) have revolutionized cancer outcomes but are limited by immune-related adverse events (irAEs), including rheumatic irAEs (Rh-irAEs). Aging is… Read More
Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study
Introduction
Immune checkpoint inhibitors-induced inflammatory arthritis (ICI-IA) affects about 5% of ICI recipients. We aimed (1) to characterize the resolution of ICI-IA during ICI… Read More
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
Objective
Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis… Read More
Chronicity of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno-Oncology Database
Objective
Immune checkpoint inhibitors (ICIs) improve overall survival (OS) and progression-free survival (PFS) in many types of malignancies but can result in off-target immune-related… Read More
Improving Knowledge Dissemination of Rheumatic Toxicities of Cancer Immunotherapy: A Web-Based Educational Initiative
https://onlinelibrary.wiley.com/doi/full/10.1002/msc.70065
We developed a web-based educational platform (www.canrio.ca) to house learning materials for practicing rheumatologists and to facilitate national and international collaboration… Read More
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group
Introduction: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA)… Read More
The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events
Immune checkpoint inhibitors (ICIs) have greatly improved survival of several cancers with historically very poor prognosis. ICIs act by stimulating the patient's own immune system… Read More
De novo Connective Tissue Disorders as Immune-related Adverse Events
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment through blocking immunoregulatory pathways, resulting in augmented antitumor responses. However, ICIs can cause inflammatory autoimmune toxicities, known… Read More
Immune Checkpoint Inhibitor associated Remitting Seronegative Symmetrical Synovitis with Pitting Edema (ICI-RS3PE): Description of a New Entity by CanRIO
Objective: Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is characterized by symmetrical synovitis with pitting edema and negative rheumatoid factor (RF). It has been… Read More